Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root
Authors:
- 13 December 2004
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 101 (51) , 17795-17800
Abstract
Fractalkine (CX3CL1) is of particular interest in atherogenesis because it can serve as an adhesion molecule and a chemokine. Fractalkine and its receptor CX3CR1 are expressed in atherosclerotic lesions of humans and mice. However, the effect of fractalkine deficiency on atherosclerosis susceptibility is unknown. Fractalkine-deficient mice on the C57BL/6 (B6) background were bred to the atherosclerosis-sensitizing B6.ApoE -/- and B6.LDLR -/- backgrounds. Compared with controls, aortic-root lesion area was unchanged in fractalkine-deficient male and female B6.ApoE -/- mice at 16 weeks of age and males at 12 weeks of age, but it was mildly reduced (30%, P = 0.005) in females at 12 weeks of age. In contrast, lesion area at the brachiocephalic artery (BCA) was reduced dramatically by ≈85% in fractalkine-deficient females [42,251 ± 26,136 μm 2 ( n = 15) vs. 6,538 ± 11,320 μm 2 ;( n = 24), P < 0.0001] and males [36,911 ± 32,504 μm 2 ( n = 24) vs. 6,768 ± 8,595 μm 2 ( n = 14); P = 0.001] at 16 weeks of age. Fractalkine-deficient B6.ApoE -/- mice were comparable with controls in body weight, plasma cholesterol, plasma high-density lipoprotein cholesterol and white blood cell counts. On the B6.LDLR -/- background, lesion areas were reduced by 35% at the aortic root ( P < 0.01) and by 50% at the BCA ( P < 0.05) in fractalkine-deficient females at 16 weeks of age. Lesions in fractalkine-deficient mice on the B6.ApoE -/- and B6.LDLR -/- backgrounds were less complex and contained significantly fewer macrophages than controls. In conclusion, the major reduction of atherosclerosis in fractalkine-deficient mice appears to be at the BCA rather than the aortic root.Keywords
This publication has 25 references indexed in Scilit:
- Site Specificity of AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Smooth Muscle Cells in Human Atherosclerotic Plaques Express the Fractalkine Receptor CX 3 CR1 and Undergo Chemotaxis to the CX 3 C Chemokine Fractalkine (CX 3 CL1)Circulation, 2003
- Genetic Background Selectively Influences Innominate Artery AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout MiceCirculation, 2003
- Interleukin-4 Deficiency Decreases Atherosclerotic Lesion Formation in a Site-Specific Manner in Female LDL Receptor−/− MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery diseaseBlood, 2001
- AtherosclerosisCell, 2001
- Theoretical and empirical issues for marker-assisted breeding of congenic mouse strainsNature Genetics, 1997
- A new class of membrane-bound chemokine with a CX3C motifNature, 1997
- Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice.Journal of Clinical Investigation, 1995